Switch theme
Sign up to access all valuation multiples
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.
1990
2.4K+
LTM Revenue $546M
LTM EBITDA $97.0M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Strides Pharma has a last 12-month revenue (LTM) of $546M and a last 12-month EBITDA of $97.0M.
In the most recent fiscal year, Strides Pharma achieved revenue of $456M and an EBITDA of $44.1M.
Strides Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Strides Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $546M | XXX | $456M | XXX | XXX | XXX |
| Gross Profit | $546M | XXX | $254M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $97.0M | XXX | $44.1M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 10% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $56.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $44.2M | XXX | -$8.3M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | -2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $264M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Strides Pharma's stock price is INR 811 (or $9).
Strides Pharma has current market cap of INR 74.8B (or $875M), and EV of INR 94.5B (or $1.1B).
See Strides Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $875M | XXX | XXX | XXX | XXX | $0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Strides Pharma has market cap of $875M and EV of $1.1B.
Strides Pharma's trades at 2.5x EV/Revenue multiple, and 29.0x EV/EBITDA.
Equity research analysts estimate Strides Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Strides Pharma has a P/E ratio of 19.8x.
See valuation multiples for Strides Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $875M | XXX | $875M | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 29.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 23.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.8x | XXX | -72.1x | XXX | XXX | XXX |
| EV/FCF | 24.1x | XXX | 22.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStrides Pharma's last 12 month revenue growth is 12%
Strides Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Strides Pharma's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Strides Pharma's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Strides Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 81% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Strides Pharma acquired XXX companies to date.
Last acquisition by Strides Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Strides Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Strides Pharma founded? | Strides Pharma was founded in 1990. |
| Where is Strides Pharma headquartered? | Strides Pharma is headquartered in India. |
| How many employees does Strides Pharma have? | As of today, Strides Pharma has 2.4K+ employees. |
| Who is the CEO of Strides Pharma? | Strides Pharma's CEO is Mr. Badree Komandur. |
| Is Strides Pharma publicy listed? | Yes, Strides Pharma is a public company listed on NSE. |
| What is the stock symbol of Strides Pharma? | Strides Pharma trades under STAR ticker. |
| When did Strides Pharma go public? | Strides Pharma went public in 2000. |
| Who are competitors of Strides Pharma? | Similar companies to Strides Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Strides Pharma? | Strides Pharma's current market cap is $875M |
| What is the current revenue of Strides Pharma? | Strides Pharma's last 12 months revenue is $546M. |
| What is the current revenue growth of Strides Pharma? | Strides Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Strides Pharma? | Current revenue multiple of Strides Pharma is 2.0x. |
| Is Strides Pharma profitable? | Yes, Strides Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Strides Pharma? | Strides Pharma's last 12 months EBITDA is $97.0M. |
| What is Strides Pharma's EBITDA margin? | Strides Pharma's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Strides Pharma? | Current EBITDA multiple of Strides Pharma is 11.4x. |
| What is the current FCF of Strides Pharma? | Strides Pharma's last 12 months FCF is $45.8M. |
| What is Strides Pharma's FCF margin? | Strides Pharma's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Strides Pharma? | Current FCF multiple of Strides Pharma is 24.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
